Enter Lingyin Li, PhD, a biochemist and professor at Stanford University’s Department of Biochemistry and the ChEM-H institute, whose groundbreaking work explores a novel immunotherapeutic strategy aimed at converting these “cold” solid tumors into “hot,” immunologically active ones. Unlike traditional immunotherapies that primarily stimulate the adaptive immune response, Dr. Li’s approach harnesses a powerful mechanism of the innate immune system centered on the small molecule cyclic GMP-AMP (cGAMP). As a rapid responder to cellular damage and pathogenic threats, cGAMP triggers immediate inflammatory signaling through the STING (stimulator of interferon genes) pathway, acting as a first line of defense.

One of the pivotal discoveries made by Li’s lab unveiled that tumors evade immune surveillance not only by silencing adaptive immunity but also by actively degrading cGAMP through overexpression of the enzyme ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). ENPP1 catalyzes the hydrolysis of extracellular cGAMP, effectively preventing it from activating STING pathways in surrounding immune cells. This degradation maintains the tumor’s cold microenvironment, allowing malignant cells to proliferate unchecked. Understanding this molecular camouflage mechanism framed the hypothesis that inhibiting ENPP1 could bolster innate immune signaling within tumors and enhance anti-cancer immunity.

Capitalizing on this insight, Dr. Li and her interdisciplinary team synthesized STF-1623, a potent and selective small-molecule inhibitor of ENPP1. This drug is designed to specifically bind to and block ENPP1 activity localized on the tumor cell surface, thereby preserving cGAMP levels within the tumor microenvironment. Their recent publication in Cell Reports Medicine (September 2025) provides compelling preclinical evidence that STF-1623 amplifies intratumoral cGAMP concentrations, which in turn activate the STING pathway in immune cells, transforming inert tumors into hotbeds of immunological activity.

In meticulous in vivo studies employing multiple mouse models—covering breast, pancreatic, colorectal, and glioblastoma cancers—STF-1623 demonstrably suppressed tumor growth without eliciting detectable adverse effects. This selective safety profile results from the drug’s mechanism of targeting ENPP1, which is highly concentrated on tumor cells but expressed at minimal levels in healthy tissues. Consequently, STF-1623 primarily acts where it is needed, mitigating systemic inflammation and associated toxicities often observed with broader immune activators.

At the molecular level, structural biology elucidated the intimate interaction between STF-1623 and ENPP1. The inhibitor occupies the enzyme’s active site, coordinating with essential zinc ions and displaying long-term binding affinity exceeding 24 hours. This durable engagement potentiates sustained inhibition of cGAMP hydrolysis, thus amplifying the persistence of cGAMP signaling in the tumor milieu. This mechanism sets STF-1623 apart from conventional STING agonists, which attempt to directly stimulate the pathway, often resulting in unrestrained inflammation and limited clinical success.

Moreover, STF-1623’s mode of action leverages endogenous cGAMP produced by cancer cells in response to genomic instability—a hallmark of tumors characterized by DNA damage and mutation burden. Cytosolic DNA leaks from the nucleus or mitochondria activate the DNA sensor cGAS, catalyzing cGAMP synthesis. However, cancer cells exploit ENPP1 to evade this innate alert system, thereby dampening immune activation. By neutralizing ENPP1, STF-1623 reinstates this ancient surveillance checkpoint, mobilizing innate immune effectors including type I interferons, dendritic cells, and natural killer cells to mount a robust anti-tumor assault.

Despite the promise of STF-1623 as a monotherapy, Dr. Li emphasizes that the inherent complexity of cancer necessitates combination strategies. Preclinical data indicate enhanced efficacy when STF-1623 is administered alongside other cancer therapies such as checkpoint inhibitors or chemotherapies. This combinatorial approach may synergistically unmask tumors to immune detection, improve infiltration of cytotoxic lymphocytes, and overcome resistance mechanisms. Such targeted activation of innate immunity at the tumor site could complement the systemic adaptive immune engagement fostered by existing immunotherapies.

Another notable advantage of STF-1623 arises from its ability to finely tune the immune response by preserving physiological cGAMP signaling, rather than artificially activating STING with synthetic agonists. This nuanced modulation of innate immunity is expected to reduce off-target effects and excessive inflammation that have plagued early clinical trials with direct STING agonists. By working with the body’s natural defense mechanisms, STF-1623 represents a paradigm shift in designing immunotherapies that precisely recalibrate tumor-immune interactions.

With promising preclinical efficacy and an encouraging safety profile, STF-1623 has recently obtained FDA clearance to initiate Phase I clinical trials. Patient enrollment is anticipated to commence shortly, marking a significant milestone in the translation of innate immune checkpoint blockade from bench to bedside. These clinical studies will critically evaluate the drug’s safety, pharmacokinetics, and preliminary anti-cancer activity in humans, laying the groundwork for potential new treatment avenues for patients with cancers unresponsive to current immunotherapies.

Dr. Li’s pioneering work at the Arc Institute, an independent nonprofit dedicated to accelerating biomedical discovery through collaborative and curiosity-driven research, exemplifies the transformative potential of innovative immune-targeted drug design. Supported by both public and private funders such as the National Institutes of Health and Angarus Therapeutics, this research integrates structural biology, immunology, and translational science to confront one of oncology’s most stubborn challenges: treating the invisible, immune-evading cold tumors.

As the field moves forward, the success of STF-1623 could inspire a broader class of innate immune checkpoint inhibitors, expanding the therapeutic arsenal against solid tumors. By illuminating the intricate crosstalk between cancer cells and the innate immune system, Dr. Li’s research ushers in a new era—one where the body’s first responders are empowered to rally a powerful, localized immune offense against elusive malignancies.

Subject of Research: Animals

Article Title: Innate immune checkpoint blockade with an ENPP1 inhibitor boosts intratumoral cGAMP to drive anti-cancer immunity

News Publication Date: 5-Sep-2025

Web References:
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00409-4

References:
Wang S., Johnson R., Carozza J., Fernandez D., Scicinski J., Verity N., Mardjuki R., Cao X., Guo Y., Papkoff J., Ray N., Li L. (2025). Innate immune checkpoint blockade with an ENPP1 inhibitor boosts intratumoral cGAMP to drive anti-cancer immunity. Cell Reports Medicine. DOI: 10.1016/j.xcrm.2025.102336

Image Credits: Raymond Rudolph

Keywords: Cancer, Biomedical engineering, Drug design

A team of researchers, led by Dr. Edgar Engleman, MD, PhD, at Stanford University, has uncovered that EPO, traditionally seen as a hematopoietic growth factor, functions as a critical switch within the immune landscape of cancer. The study, published in the prestigious journal Science on April 24, 2025, demonstrates that by blocking EPO signaling, formerly “cold” tumors—those that evade immune detection—can be converted into “hot” tumors, rich with activated cancer-fighting immune cells, particularly T lymphocytes. This transformation holds profound therapeutic implications, especially when combined with immune checkpoint inhibitors like anti-PD-1 antibodies, such as the commercially available Keytruda.

Cold tumors are a notorious challenge in oncology because their immune-resistant nature allows unchecked cancer growth. Dr. Engleman’s group utilized sophisticated genome editing techniques to develop multiple mouse models of liver cancer that closely mirror human disease, including its genetic mutations, histological features, and response patterns to existing therapies. Leveraging these models, they observed that tumors exhibiting resistance to anti-PD-1 therapy also showed markedly elevated levels of EPO compared to tumors infiltrated by immune cells. This correlation indicated a previously unappreciated role for EPO in fostering an immunosuppressive tumor microenvironment.

Further investigation revealed that tumor-associated hypoxia, a hallmark of many solid tumors, is a driving force behind the increased expression of EPO within cold tumors. Hypoxia stimulates cancer cells to produce signals that elevate EPO levels, which, in turn, act on macrophages within the tumor. These macrophages, once activated by EPO through its receptor, shift towards an immunosuppressive phenotype, actively repelling T cells and quelling their anti-cancer activities. This crosstalk essentially creates an immune-privileged niche, enabling tumors to grow unchecked and resist current immunotherapies.

Strikingly, when the researchers genetically disrupted the tumor cells’ ability to produce EPO, the formerly cold tumors transformed into hot, inflamed tumors, abundant with active T cells. Conversely, artificially elevating EPO levels in hot tumors induced immune suppression, enabling tumor progression. These elegant experiments solidify the causal role of tumor-derived EPO as an immunosuppressive switch, shifting the tumor-immune balance toward immune evasion.

To probe the therapeutic potential of these findings, the team evaluated the combined blockade of the EPO signaling pathway and PD-1. In murine models carrying cold liver tumors, neither anti-PD-1 therapy nor controls alone improved survival beyond eight weeks post tumor induction. However, mice engineered to have macrophages deficient in EPO receptors exhibited significantly extended survival, with 40% alive at 18 weeks after tumor initiation. Strikingly, when these macrophage-specific EPO receptor knockout mice received anti-PD-1 therapy, survival extended to the full duration of the experiment, with complete tumor regression in most cases.

These results underscore that interrupting EPO signaling effectively reactivates the immune system’s ability to recognize and destroy tumors, overcoming one of the major barriers in cancer immunotherapy. Dr. Engleman emphasized that targeting EPO or its receptor could complement existing checkpoint blockade therapies, thus widening the spectrum of cancers responsive to immunotherapy—particularly liver, pancreatic, colorectal, breast, and prostate cancers, which are typically resistant to anti-PD-1 therapy.

The clinical implications extend beyond liver cancer, as analyses of patient tumor databases revealed a consistent association between high EPO expression and poorer survival across multiple tumor types, including kidney, breast, colon, and skin cancers. This highlights EPO’s broader role as a central regulator within the tumor microenvironment’s immune modulation.

Despite the promise, Dr. Engleman cautions against indiscriminate systemic inhibition of EPO due to its essential physiological role in red blood cell production, raising concerns about anemia as a potential side effect. As an alternative, strategies are under exploration to selectively target EPO receptors expressed on tumor-associated macrophages, aiming to disrupt immunosuppression without compromising erythropoiesis. This targeted approach may offer a safer therapeutic window while enhancing immune-mediated tumor clearance.

This discovery also provides a mechanistic explanation for previous clinical observations that administration of EPO to cancer patients with anemia sometimes accelerated tumor growth—a phenomenon that had puzzled clinicians and researchers for years and led to FDA black box warnings on EPO drugs. By elucidating EPO’s immunosuppressive function within tumors, the study reconciles these clinical findings within a comprehensive biological framework.

The interdisciplinary collaboration for this research included contributions from the New York Blood Center and ImmunEdge Inc., a biotechnology company co-founded by Dr. Chiu, the study’s lead author, and Dr. Engleman. Their joint efforts exemplify how academic and industrial partnerships can accelerate the translation of basic scientific insights into therapeutic innovations.

Looking forward, Dr. Engleman and his team are advancing preclinical development of EPO pathway inhibitors and designing clinical strategies to test their efficacy in human cancers. The anticipated integration of EPO receptor blockade with immune checkpoint therapy holds promise to not only improve patient outcomes but also to expand the reach of immunotherapy to presently refractory cancers.

This pioneering research reshapes fundamental concepts in cancer immunity by unveiling an unexpected role for erythropoietin—a decades-old molecule—in modulating tumor immune escape. As the field embraces these insights, the future of cancer treatment may soon harness EPO-targeted strategies to reinvigorate anti-tumor immunity and bring new hope to patients worldwide.

Subject of Research: Animals

Article Title: Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity

News Publication Date: 24-Apr-2025

A stalwart in the realm of medical research, Dr. Mackall serves as the Ernest and Amelia Gallo Family Professor as well as a professor of pediatrics and medicine at Stanford University. Her leadership extends to the founding directorship of the Stanford Center for Cancer Cell Therapy, alongside her role as the director of the Parker Institute for Cancer Immunotherapy. Notably, Mackall’s research spans a decade of innovative studies aimed at deciphering the intricate mechanisms by which the immune system can be leveraged to fight malignancies, specifically highlighting her contributions to CAR T-cell therapies—a revolutionary advancement in personalized cancer treatment.

Mackall’s illustrious career is characterized by her insightful advancements in the understanding of T-cell homeostasis, particularly through her pivotal discovery of interleukin-7 (IL-7) roles. This cytokine plays a vital role in maintaining T-cell populations, and her work has laid the theoretical groundwork for various therapies that utilize this biological knowledge to enhance immune responses against cancer. Her path-breaking clinical trials have redefined treatment algorithms, especially for pediatric cancer patients, establishing her reputation as a leading figure in the field.

One of Mackall’s crowning achievements is her pioneering research surrounding chimeric antigen receptor (CAR) T-cells. As one of the first researchers to investigate CD19-targeted CAR T-cell therapy in pediatric patients suffering from B-cell acute lymphoblastic leukemia, her studies demonstrated remarkable response rates, positioning CAR T-cell therapy as a therapeutic mainstay in treating various hematological malignancies. However, Mackall is not one to rest on her laurels, as she continually investigates the underlying mechanisms of resistance that can diminish the effectiveness of these therapies.

A notable impact of Mackall’s work is her recent focus on extending the applicability of CAR T-cell therapies to solid tumors, which historically have posed a significant challenge for oncologists. Her ongoing research is poised to broaden the horizons of CAR T-cell therapy, aiming to transition its benefits from hematologic malignancies into the realm of solid tumors, thereby fulfilling a major unmet need in the field of cancer treatment. This ambitious endeavor reflects her commitment to improving outcomes for all cancer patients, particularly those who have fewer viable treatment options.

Dr. Mackall’s influence extends beyond her research portfolio; she has played an instrumental role in shaping the future of cancer immunotherapy through her dedicated involvement in various committees and working groups within the AACR. This includes membership and leadership roles in committees aimed at advancing pediatric oncology, education, and immunotherapy research initiatives. Her relentless dedication to fostering collaboration among scientists and clinicians ensures that the pursuit of innovative cancer therapies remains at the forefront of medical research.

The AACR-CRI Lloyd J. Old Award was initiated in 2013 with the goal of honoring outstanding cancer immunologists whose work has expanded our understanding of the immune response to cancer. Dr. Mackall’s selection as this year’s honoree underscores not only her individual achievements but also the evolving nature of cancer research as a collaborative and interdisciplinary endeavor. The award ceremony will take place during the AACR Annual Meeting, where Mackall will also deliver an award lecture detailing her groundbreaking findings and contributions to cancer research.

In light of her numerous accolades, including her recent election to the AACR Board of Directors, Dr. Mackall’s reputation is further solidified by an impressive list of awards recognizing her extraordinary contributions to the field of oncology. Her dedication has not gone unnoticed, earning her numerous recognitions from esteemed institutions and organizations within the medical and scientific communities. These awards are a testament to her relentless pursuit of excellence and her pioneering spirit, which continues to inspire both her peers and the next generation of cancer researchers.

Mackall’s influence resonates not only through her research and administrative roles but also in her commitment to mentoring young scientists. By fostering an environment of innovation and inquiry, she plays a crucial part in guiding emerging researchers in the field of oncology. Her mentorship is invaluable in shaping the future of cancer treatment as she encourages aspiring scientists to challenge the status quo and explore novel therapeutic approaches that could redefine patient care.

As the field of cancer research advances, the importance of collaboration and knowledge sharing becomes increasingly paramount. Dr. Mackall exemplifies this collaborative spirit through her participation in multi-institutional research initiatives, including her roles on various editorial boards and steering committees. Her involvement ensures that significant findings are disseminated widely, affording oncologists and researchers alike the opportunity to leverage shared information to enhance treatment options for cancer patients.

In addition to her scientific endeavors, Dr. Mackall often emphasizes the necessity of translating research findings into clinically actionable strategies. This crucial step bridges the gap between laboratory discoveries and patient care, ensuring that the latest innovations in cancer immunotherapy reach the individuals who need them most. Her commitment to translational research exemplifies a holistic approach to cancer treatment, where innovation is constantly infused into clinical practice.

With the AACR-CRI Lloyd J. Old Award in hand and an ever-expanding legacy, Crystal L. Mackall stands at the forefront of cancer immunology, a leader whose research continues to break barriers and transform the lives of countless patients. As she prepares to share her insights at the upcoming annual meeting, the scientific community eagerly anticipates the next chapter of her groundbreaking work. Her contributions will not only influence the immediate landscape of cancer research but also shape the future trajectory of treatment paradigms for years to come.

As we navigate the complex world of cancer treatment, the importance of visionary leaders like Dr. Mackall cannot be overstated. Her influence, expertise, and dedication serve as a guiding light for current and future generations of researchers, clinicians, and patients alike. The journey of cancer immunotherapy is ongoing, and with pioneers like Mackall leading the way, the horizons of hope continue to expand for patients combating this formidable disease.

Subject of Research: Cancer Immunotherapy and CAR T-cell Therapy
Article Title: Crystal L. Mackall Honored with Prestigious Cancer Immunology Award
News Publication Date: [Insert Date]
Web References: [Insert relevant URLs if applicable]
References: [Insert relevant citations if applicable]
Image Credits: [Insert if applicable]

Keywords: Cancer Immunology, CAR T-cell Therapy, Cancer Research, Pediatric Oncology, Translational Research, T-cell Homeostasis, Immune Response, Clinical Trials, Cancer Treatment, AACR-CRI Award

This extensive investigation marks a pioneering effort to sift through the extensive data garnered from millions of cancer patients. Prior studies have identified countless genetic variants associated with cancer risk, but the vast majority remained unverified in terms of their functional relevance. The Stanford researchers employed an innovative approach to differentiate between incidental genetic changes and those that are genuinely consequential in promoting cancer. This distinction is vital in developing targeted therapies and effective screening strategies for individuals at high risk of the disease.

Armed with a compendium of genomic data, Stanford’s researchers meticulously pinpointed nearly 400 SNVs rooted in inherited DNA that are crucial for cancer initiation and progression. These variants play pivotal roles in several biological pathways linked to crucial cellular functions such as DNA damage repair, cellular energetics, and the interaction of cells with their microenvironment. Each of these pathways offers potential therapeutic targets, marking a significant step forward in the fight against cancer through personalized medicine.

One particularly salient aspect of their research involves the germline genome, which encompasses the genetic material inherited from one’s parents. Unlike somatic mutations that accumulate during an individual’s life, these inherited variants can set the stage for cancer risk right from conception. Well-known examples of inherited mutations, like those found in the BRCA1 and BRCA2 genes, have been extensively studied for their association with breast and ovarian cancers, underscoring the need for more robust genetic screening tools that can take a wider array of variants into account.

The recent research not only identified variants located within coding regions, which direct protein synthesis, but it also shed light on regulatory regions that influence gene expression. The regulatory elements provide critical insights into how genes can be activated or suppressed in response to different cellular conditions. By capturing these complex interactions, the researchers were able to construct a clearer picture of how certain genetic variations contribute to cancer predisposition, thus enhancing our understanding of cancer biology as a whole.

A noteworthy methodology employed by the Stanford team involved the use of massively parallel reporter assays—a cutting-edge technique that enables researchers to analyze the impact of numerous genetic variants simultaneously. By tagging DNA sequences with unique bar codes, they could measure which variants altered gene expression within relevant cellular environments. This meticulous analysis allowed the researchers to differentiate between variants that merely correlated with cancer and those that actively modulated gene activity, providing insights that are crucial for understanding cancer risk and progression.

The implications of this research extend into the realm of clinical applications, where it could inform novel genetic screening tools aimed at evaluating cancer risk across diverse populations. By identifying functional genetic variants, the study presents an opportunity to create individualized risk profiles that could guide preventive strategies and tailored treatment options. This advancement has the potential for significant impact not only in oncology but also in the broader field of genetic research and personalized medicine.

Furthermore, the study’s findings highlight an intriguing connection between immune responses and cancer risk. The researchers highlighted specific genes associated with inflammation following their analyses, further contributing to the ongoing discourse about the role of the immune system in cancer development. The established link between inflammation and cancer has long been recognized, yet the precise mechanisms driving this interaction have remained elusive. The new findings may illuminate how both cancer cells and the immune response interact to foster an environment conducive to cancer growth.

Khavari emphasizes the value of this research by articulating how the findings represent a cartographic map of functional genetic variants that can shape an individual’s lifetime cancer risk. While previous studies focused on variant identification, this research breaks new ground by illustrating the physiological relevance of these variants in driving cancer. As the scientific community endeavors to translate these findings into clinical relevance, the potential for developing new therapies based on genetic insights appears promising.

In the realm of funding and support, this pioneering research received backing from esteemed organizations, including the U.S. Veterans Affairs Office of Research and Development and the National Institutes of Health. Such support underscores the importance of this research in addressing a public health crisis that claims millions of lives annually. It paves the way for longitudinal studies that can bring to light additional variants associated with cancer susceptibility and guide future therapeutic developments.

As the scientific community begins to integrate these insights into practice, a clearer picture of cancer predisposition will emerge. This research provides a robust foundation for developing comprehensive genetic assessments aimed at identifying individuals at high risk, facilitating earlier interventions and potential lifestyle modifications that could mitigate cancer risk. Thus, the anticipated impact of this study may lead not only to new cancer treatment paradigms but also to life-saving screening measures that could transform preventive medicine.

The research, published in the prestigious journal Nature Genetics, appears to be a harbinger of a new era in cancer biology, emphasizing the intricate interplay between genetics and environmental factors in disease development. This intricate relationship invites further exploration into how we might manipulate these pathways for therapeutic benefits, dramatically altering the landscape of cancer treatment in the years to come.

With time, as the technologies for genetic research and analysis continue to advance, the landscape of cancer prediction and prevention will likely evolve, making this foundational study a critical piece of the puzzle. Researchers around the globe are expected to leverage these findings, enhancing our understanding of inherited cancer risk and paving the way for innovative therapies and preventative strategies that could save countless lives.

In summary, Stanford’s team has underscored the complexities of genetic risk factors in cancer development, promising future avenues for research and potentially heralding a new chapter in personalized medicine that could offer hope to patients and families affected by cancer.

Subject of Research: Cells
Article Title: Functional analysis of cancer-associated germline risk variants
News Publication Date: 17-Feb-2025
Web References: Nature Genetics
References: Not provided
Image Credits: Not provided

Keywords: Cancer risk, Cancer research, Genetic variants, Personalized medicine, Germline genome, Regulatory regions, Single nucleotide variants.